United Therapeutics Corp

United Therapeutics’ Tyvaso breakthrough in the TETON‑1 study sparks investor buzz, boosting pricing targets and buy ratings as the company scales IPF access while navigating reimbursement hurdles.

United Therapeutics’ analyst upgrades to mid‑$600s reflect strong QALY‑based pricing, digital‑manufacturing gains and patient‑access wins that drive 8‑10 % growth.

United Therapeutics reveals its strategy to dominate pulmonary hypertension: market access, competitive edge, patent plans, and M&A prospects—all at TD Cowen.

United Therapeutics updates at JHC: focus on prostacyclin PAH therapies, value‑based contracts, patent strategy, and potential M&A for growth.

United Therapeutics Corporation reported record third-quarter 2025 results, exceeding Wall Street expectations with earnings per share of $7.16 and revenue of $799 million, driven by growth in its core product portfolio and strong operating cash flo…

United Therapeutics’ stock has seen a notable 11.9% gain since its last earnings report, driven by the company’s growing financial performance and investor confidence.

United Therapeutics and MannKind have expanded their partnership, leading to increased R&D efforts, improved product pipelines, and enhanced market presence in the pharmaceutical industry.

United Therapeutics has reported strong quarterly earnings, with a stock price of $313.22 and impressive price-to-earnings and price-to-book ratios, sparking interest among investors and analysts.

United Therapeutics has released its quarterly earnings report, highlighting fluctuations in its stock price and key financial metrics such as a price-to-earnings ratio of 12.22.

The company’s annual meeting and board meeting have led to significant developments, including a new vaccine production and a major aircraft order.